Hain B, Jude B, Xu H, Smuin D, Fox E, Elfar J, et al. Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy. J Bone Miner Res. 2020;35:368-381 pubmed publisher

Gomes A, Ilter D, Low V, Rosenzweig A, Shen Z, Schild T, et al. Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer Cell. 2019;36:402-417.e13 pubmed publisher

Bing Y, Wund Z, Abratte T, Borlle L, Kang S, Southard T, et al. Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas. Cancer Cell Int. 2018;18:192 pubmed publisher

Ji J, Zuo P, Wang Y. Enhanced Antiproliferative Effect of Carboplatin in Cervical Cancer Cells Utilizing Folate-Grafted Polymeric Nanoparticles. Nanoscale Res Lett. 2015;10:453 pubmed publisher

Clemente Vicario F, Alvarez C, ROWELL J, Roy S, London C, Kisseberth W, et al. Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. PLoS ONE. 2015;10:e0142007 pubmed publisher

Yang L, Guo J, Shen Y, Cai J, Xiong Z, Dong W, et al. Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage IB2-IIB cervical cancer. Int J Clin Exp Med. 2015;8:13690-8 pubmed

Rohnalter V, Roth K, Finkernagel F, Adhikary T, Obert J, Dorzweiler K, et al. A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget. 2015;6:40005-25 pubmed publisher

Khurana A, Roy D, Kalogera E, Mondal S, Wen X, He X, et al. Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. Oncotarget. 2015;6:36354-69 pubmed publisher

Tonsing Carter E, Bailey B, Saadatzadeh M, Ding J, Wang H, Sinn A, et al. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther. 2015;14:2850-63 pubmed publisher

Meker S, Braitbard O, Margulis Goshen K, Magdassi S, Hochman J, Tshuva E. Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity. Molecules. 2015;20:18526-38 pubmed publisher

Jiang N, Chen W, Zhang J, Li Y, Zeng X, Zhang T, et al. Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells. Mol Med Rep. 2015;12:7239-46 pubmed publisher

Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem. 2015;37:276-83 pubmed publisher

Mao D, Che J, Han S, Zhao H, Zhu Y, Zhu H. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells. Mol Med Rep. 2015;12:6635-41 pubmed publisher

Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015;112:E4600-9 pubmed publisher

Antonissen G, Devreese M, De Baere S, Hellebuyck T, Van de Maele I, Rouffaer L, et al. Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species. PLoS ONE. 2015;10:e0134177 pubmed publisher

Massey A. Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC. PLoS ONE. 2015;10:e0134306 pubmed publisher

Mizuno T, Sato W, Ishikawa K, Terao Y, Takahashi K, Noda Y, et al. Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury. Onco Targets Ther. 2015;8:1701-6 pubmed publisher

Lee J, Gordon N, Trepel J, Lee M, Yu M, Kohn E. Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. J Transl Med. 2015;13:239 pubmed publisher

Halfter K, Ditsch N, Kolberg H, Fischer H, Hauzenberger T, von Koch F, et al. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study. BMC Cancer. 2015;15:519 pubmed publisher

Jin H, Dong Y, Zhang H, Cui Y, Xie K, Lou G. shRNA Depletion of cIAP1 Sensitizes Human Ovarian Cancer Cells to Anticancer Agent-Induced Apoptosis. Oncol Res. 2014;22:167-76 pubmed publisher

Zhang N, Zhang L, Liu Z, Huang G, Zhang L, Yi J, et al. Therapeutic efficacy of paclitaxel and carboplatin via arterial or venous perfusion in rabbits with VX-2 tongue cancer. Int J Clin Exp Med. 2015;8:4979-88 pubmed

Mohell N, Alfredsson J, Fransson Ã, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6:e1794 pubmed publisher

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust K, Limbart D, et al. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015;8:210-6 pubmed publisher

Genestreti G, Di Battista M, Cavallo G, Bartolotti M, Brandes A. Maintenance therapy in non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15:839-46 pubmed publisher

Zhou D, Xu L, Luo Y, He F, Huang J, Zhang Y, et al. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015;21:5582-90 pubmed publisher

Tang Y, Wang Y, Deosarkar S, Soroush F, Kiani M, Wang B. Fast, Stable Induction of P-Glycoprotein-mediated Drug Resistance in BT-474 Breast Cancer Cells by Stable Transfection of ABCB1 Gene. Anticancer Res. 2015;35:2531-8 pubmed

Yang M, Xu Z, Wang Q, Zhang A, Min J. A hyposensitive anticancer drug induces higher surface expression and release of heat shock proteins in a human hepatocellular carcinoma cell line. Mol Med Rep. 2015;12:2879-85 pubmed publisher

Ito Y, Kikuchi E, Tanaka N, Kosaka T, Suzuki E, Mizuno R, et al. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. BMC Cancer. 2015;15:324 pubmed publisher

Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anestakis D, Zarogoulidis K. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal. 2015;27:1576-88 pubmed publisher

Biswas R, Mondal A, Ahn J. Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice. J Photochem Photobiol B. 2015;148:118-127 pubmed publisher

Andrei A, Hall A, Smith A, Bascuñana C, Malina A, Connor A, et al. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Lett. 2015;364:8-16 pubmed publisher

Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, et al. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. Cancer Lett. 2015;362:218-28 pubmed publisher

Karginova O, Siegel M, Van Swearingen A, Deal A, Adamo B, Sambade M, et al. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther. 2015;14:920-30 pubmed publisher

Chen S, Kuo C, Pan H, Tsou T, Yeh S, Chang J. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Biochem Pharmacol. 2015;95:28-37 pubmed publisher

Weber J, D Angelo S, Minor D, Hodi F, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-84 pubmed publisher

Krishnan S, Nair B, Sareddy G, Roy S, Natarajan M, Suzuki T, et al. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. Breast Cancer Res Treat. 2015;150:487-99 pubmed publisher

Zhang B, Wang Y, Gong H, Zhao H, Lv X, Yuan G, et al. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC). Int J Clin Exp Pathol. 2015;8:25-37 pubmed

Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, et al. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer. 2015;51:879-892 pubmed publisher

Knezevic J, Pfefferle A, Petrovic I, Greene S, Perou C, Rosen J. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015;34:5997-6006 pubmed publisher

Yan L, Wang C, Lin B, Liu J, Liu D, Hou R, et al. Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 2015;113:17-25 pubmed publisher

Lenkala D, Gamazon E, LaCroix B, Im H, Huang R. MicroRNA biogenesis and cellular proliferation. Transl Res. 2015;166:145-51 pubmed publisher

Kang J, Kang H, Kim I, Lee H, Ha J, Yeo C, et al. Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin. Exp Biol Med (Maywood). 2015;240:1416-25 pubmed publisher

Yang X, Zheng J, Song Q, Xie F, Tang J, Chen J, et al. Determination methods for the anticancer drug dicycloplatin, a supramolecule assembled through hydrogen bonding. Analyst. 2015;140:2704-12 pubmed publisher

Gentzler R, Johnson M. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist. 2015;20:299-306 pubmed publisher

Yanagihara N, Kobayashi D, Kuribayashi K, Tanaka M, Hasegawa T, Watanabe N. Significance of SALL4 as a drug‑resistant factor in lung cancer. Int J Oncol. 2015;46:1527-34 pubmed publisher

Hosokawa Y, Takahashi H, Inoue A, Kawabe Y, Funahashi Y, Kameda K, et al. Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. Biochim Biophys Acta. 2015;1850:1197-205 pubmed publisher

Eppler S, Gordon M, Redfern C, Trudeau C, Xu N, Han K, et al. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015;26:448-55 pubmed publisher

Laemmle A, Hahn D, Hu L, Rüfenacht V, Gautschi M, Leibundgut K, et al. Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Mol Genet Metab. 2015;114:438-44 pubmed publisher

Horibe S, Matsuda A, Tanahashi T, Inoue J, Kawauchi S, Mizuno S, et al. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci. 2015;124:31-40 pubmed publisher

Moraleja I, Moreno Gordaliza E, Esteban Fernández D, Mena M, Linscheid M, Gomez Gomez M. A shotgun approach for the identification of platinum-protein complexes. Anal Bioanal Chem. 2015;407:2393-403 pubmed publisher

Grilley Olson J, Keedy V, Sandler A, Moore D, Socinski M, Stinchcombe T. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist. 2015;20:105-6 pubmed publisher

Patel S, Kusano A, Truong A, Stelzer K, Laramore G. Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma. Am J Clin Oncol. 2015;38:47-50 pubmed publisher

Spigel D, Patel J, Reynolds C, Garon E, Hermann R, Govindan R, et al. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in. J Thorac Oncol. 2015;10:353-9 pubmed publisher

Kondo R, Watanabe S, Ishikawa D, Tanaka T, Ohshima Y, Asakawa K, et al. [A case of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin]. Gan To Kagaku Ryoho. 2014;41:2607-9 pubmed

Teng P, Bateman N, Darcy K, Hamilton C, Maxwell G, Bakkenist C, et al. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015;136:554-61 pubmed publisher

Atanaskova Mesinkovska N, Conic R, Kiracofe E, Vidimos A. Treatment of invasive squamous cell carcinomas in an open Clagett window. Dermatol Surg. 2015;41:170-2 pubmed publisher

Wang Y, Han E, Xing Q, Yan J, Arrington A, Wang C, et al. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Lett. 2015;358:170-179 pubmed publisher

Dilling T. Radiation dose in non-small cell lung cancer: too much of a good thing?. Int J Radiat Oncol Biol Phys. 2014;90:979-82 pubmed publisher

Yang B, Lowe J, Schweins R, Edler K. Small angle neutron scattering studies on the internal structure of poly(lactide-co-glycolide)-block-poly(ethylene glycol) nanoparticles as drug delivery vehicles. Biomacromolecules. 2015;16:457-64 pubmed publisher

Makharza S, Vittorio O, Cirillo G, Oswald S, Hinde E, Kavallaris M, et al. Graphene oxide - gelatin nanohybrids as functional tools for enhanced Carboplatin activity in neuroblastoma cells. Pharm Res. 2015;32:2132-43 pubmed publisher

Meier J, Haendler B, Seidel H, Groth P, Adams R, Ziegelbauer K, et al. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis. Cancer Med. 2015;4:253-67 pubmed publisher

Connolly R, Leal J, Goetz M, Zhang Z, Zhou X, Jacobs L, et al. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56:31-7 pubmed publisher

Keitel U, Scheel A, Thomale J, Halpape R, Kaulfuß S, Scheel C, et al. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget. 2014;5:11778-91 pubmed

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-77 pubmed publisher

Shinde A, Zhai J, Yu K, Frankel P, Yim J, Luu T, et al. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. Breast. 2015;24:18-23 pubmed publisher

Reddy Ammakkanavar N, Matei D, Abonour R, Einhorn L. High-dose chemotherapy for recurrent ovarian germ cell tumors. J Clin Oncol. 2015;33:226-7 pubmed publisher

Cohn D, Barnett J, Wenzel L, Monk B, Burger R, Straughn J, et al. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecol Oncol. 2015;136:293-9 pubmed publisher

Rithirangsriroj K, Manchana T, Akkayagorn L. Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol. 2015;136:82-6 pubmed publisher

Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, et al. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecol Oncol. 2015;136:112-20 pubmed publisher

Choi S, Choi J, Wang K, Phi J, Lee J, Park K, et al. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors. Neuro Oncol. 2015;17:810-21 pubmed publisher

Doebele R, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015;121:883-92 pubmed publisher

Cummings C, Linger R, Cohen R, Sather S, Kirkpatrick G, Davies K, et al. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 2014;5:10434-45 pubmed

Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Oncol Rep. 2015;33:403-12 pubmed publisher

O Shaughnessy J, Schwartzberg L, Danso M, Miller K, Rugo H, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32:3840-7 pubmed publisher

Xu N, Redfern C, Gordon M, Eppler S, Lum B, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014;74:1251-60 pubmed publisher

Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, et al. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201). Jpn J Clin Oncol. 2015;45:115-8 pubmed publisher

Kenicer J, Spears M, Lyttle N, Taylor K, Liao L, Cunningham C, et al. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer. 2014;14:762 pubmed publisher

Dong R, Qiu H, Du G, Wang Y, Yu J, Mao C. Restoration of microRNA‑218 increases cellular chemosensitivity to cervical cancer by inhibiting cell‑cycle progression. Mol Med Rep. 2014;10:3289-95 pubmed publisher

Friel A, Zhang L, Pru C, Clark N, McCallum M, Blok L, et al. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Lett. 2015;356:434-42 pubmed publisher

Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, et al. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer C. Cancer Chemother Pharmacol. 2014;74:1149-57 pubmed publisher

Lee C, Lord S, Grunewald T, Gebski V, Hardy Bessard A, Sehouli J, et al. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol. 2015;136:18-24 pubmed publisher

Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, et al. Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Oncotarget. 2014;5:7776-87 pubmed

Yang Hartwich Y, Soteras M, Lin Z, Holmberg J, Sumi N, Craveiro V, et al. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2015;34:3605-16 pubmed publisher

Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S, Oka M. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 2014;14:722 pubmed publisher

van Maldegem A, Benson C, Rutkowski P, Blay J, van den Berg H, Placzke J, et al. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. Pediatr Blood Cancer. 2015;62:40-4 pubmed publisher

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, et al. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemother Pharmacol. 2014;74:1159-66 pubmed publisher

Narui K, Ishikawa T, Satake T, Adachi S, Yamada A, Shimada K, et al. Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy. Eur J Surg Oncol. 2015;41:94-9 pubmed publisher

King E, Kislukhin G, Walters K, Long A. Using Drosophila melanogaster to identify chemotherapy toxicity genes. Genetics. 2014;198:31-43 pubmed publisher

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Clin Cancer Res. 2014;20:5496-506 pubmed publisher

Noyes A, Lonial K, Siegel R. Tumor lysis syndrome in a nonsmall cell lung cancer. Conn Med. 2014;78:421-3 pubmed

Rivard C, Geller M, Schnettler E, Saluja M, Vogel R, Saluja A, et al. Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. Gynecol Oncol. 2014;135:318-24 pubmed publisher

Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, et al. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PLoS ONE. 2014;9:e105526 pubmed publisher

Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol. 2015;141:323-31 pubmed publisher

Yagi Y, Maeda T, Yoshimitsu Y, Sakuma H. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy]. Gan To Kagaku Ryoho. 2014;41:995-7 pubmed

Lewin J, Cullinane C, Akhurst T, Waldeck K, Watkins D, Rao A, et al. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging. 2015;42:25-32 pubmed publisher

Zhang Z, Zhang H, Hu Z, Wang P, Wan J, Li B. Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells. Oncol Lett. 2014;8:1348-1354 pubmed

Lezcano C, Kleffel S, Lee N, Larson A, Zhan Q, DoRosario A, et al. Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts. Lab Invest. 2014;94:1092-102 pubmed publisher

Utku S, Ozçelik A, Gumus F, Yilmaz S, Arsoy T, Açik L, et al. Synthesis, in-vitro cytotoxic activity and DNA interactions of new dicarboxylatoplatinum(II) complexes with 2-hydroxymethylbenzimidazole as carrier ligands. J Pharm Pharmacol. 2014;66:1593-605 pubmed publisher

Bryant C, Rawlinson R, Massey A. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014;14:570 pubmed publisher

Saba N, Hurwitz S, Magliocca K, Kim S, Owonikoko T, Harvey D, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014;120:3940-51 pubmed publisher

Sullivan I, Salazar J, Majem M, Pallares C, del Rio E, Paez D, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353:160-6 pubmed publisher

Johnson C, Green D, Zoon K. Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res. 2015;35:55-62 pubmed publisher

Lheureux S, N Diaye M, Blanc Fournier C, Dugué A, Clarisse B, Dutoit S, et al. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma. Int J Cancer. 2015;136:E340-50 pubmed publisher

Yamasaki S, Tanimoto K, Kohno K, Kadowaki M, Takase K, Kondo S, et al. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Ann Hematol. 2015;94:65-9 pubmed publisher

Najjar F, Alammar M, Bachour M, Almalla N, Altahan M, Alali A, et al. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy. J Cancer Res Clin Oncol. 2015;141:119-25 pubmed publisher

Wang Y, Cárdenas H, Fang F, Condello S, Taverna P, Segar M, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922-36 pubmed publisher

Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y, et al. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol. 2015;20:566-73 pubmed publisher

Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, et al. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. Oncotarget. 2014;5:6191-205 pubmed

Tzeng T, Cao L, Fu Y, Zeng H, Cheng W. Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin. PLoS ONE. 2014;9:e101664 pubmed publisher

Tsubamoto H, Sonoda T, Inoue K. Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer. Anticancer Res. 2014;34:3839-44 pubmed

Tirmazy S, Barthakur U, El Modir A, Anwar S, Fernando I. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin. Anticancer Res. 2014;34:3793-8 pubmed

Petrillo M, Zannoni G, Tortorella L, Pedone Anchora L, Salutari V, Ercoli A, et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol. 2014;211:632.e1-8 pubmed publisher

Ishikura H, Kumihashi Y, Kimura S, Matsuoka Y, Matsumoto D. [Clinical experience of the use of pemetrexed (PEM) combined with cisplatin (CDDP)/Carboplatin (CBDCA) followed by long-term maintenance PEM in patients with non-squamous non-small cell lung cancer]. Gan To Kagaku Ryoho. 2014;41:623-6 pubmed

Fehr M, Geldart T, Klingbiel D, Cathomas R. Measurement or estimation of glomerular filtration rate in seminoma patients: quite another cup of tea. Eur J Cancer. 2014;50:2176-7 pubmed publisher

Lin C, Wen C, Aljuffali I, Huang C, Fang J. Quantiosomes as a multimodal nanocarrier for integrating bioimaging and Carboplatin delivery. Pharm Res. 2014;31:2664-76 pubmed publisher

Langer C, Novello S, Park K, Krzakowski M, Karp D, Mok T, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014;32:2059-66 pubmed publisher

Shepherd S, Macpherson I, White J, Mark P. Response to: 'Letter to the editor, European Journal of Cancer', commenting on 'Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma'. Eur J Cancer. 2014;50:2178-9 pubmed publisher

Riquelme E, Suraokar M, Behrens C, Lin H, Girard L, Nilsson M, et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014;20:3849-61 pubmed publisher

Sadhukha T, Prabha S. Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin. AAPS PharmSciTech. 2014;15:1029-38 pubmed publisher

Wilkinson Ryan I, Binder P, Pourabolghasem S, al Hammadi N, Fuh K, Hagemann A, et al. Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. Gynecol Oncol. 2014;134:24-8 pubmed publisher

Hall M, Telma K, Chang K, Lee T, Madigan J, Lloyd J, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014;74:3913-22 pubmed publisher

Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, et al. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2014;74:37-43 pubmed publisher

Tsubamoto H, Sonoda T, Yamasaki M, Inoue K. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer. Anticancer Res. 2014;34:2481-7 pubmed

Taylor S, Beck T, Krivak T, Zorn K, Kelley J, Edwards R. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecol Oncol. 2014;134:68-72 pubmed publisher

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014;50:1819-1828 pubmed publisher

Arend R, Londoño Joshi A, Samant R, Li Y, Conner M, Hidalgo B, et al. Inhibition of Wnt/?-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134:112-20 pubmed publisher

Beltran P, Calzone F, Mitchell P, Chung Y, Cajulis E, Moody G, et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res. 2014;20:2947-58 pubmed publisher

Gopinathan N, Yang B, Lowe J, Edler K, Rigby S. NMR cryoporometry characterisation studies of the relation between drug release profile and pore structural evolution of polymeric nanoparticles. Int J Pharm. 2014;469:146-58 pubmed publisher

Shusharina N, Cho J, Sharp G, Choi N. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. Int J Radiat Oncol Biol Phys. 2014;89:137-44 pubmed publisher

Takeoka H, Yamada K, Azuma K, Zaizen Y, Yamashita F, Yoshida T, et al. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. Jpn J Clin Oncol. 2014;44:472-8 pubmed publisher

Au Yeung G, Webb P, deFazio A, Fereday S, Bressel M, Mileshkin L. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol. 2014;133:16-22 pubmed publisher

Slaughter K, Thai T, Penaroza S, Benbrook D, Thavathiru E, Ding K, et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014;133:11-5 pubmed publisher

Feldman T, Mato A, Chow K, Protomastro E, Yannotti K, Bhattacharyya P, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014;166:77-83 pubmed publisher

Shields C, Manjandavida F, Lally S, Pieretti G, Arepalli S, Caywood E, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453-60 pubmed publisher

Morichika D, Sato Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, et al. Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report. Jpn J Clin Oncol. 2014;44:501-5 pubmed publisher

Glasspool R, Brown R, Gore M, Rustin G, McNeish I, Wilson R, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110:1923-9 pubmed publisher

Chan R, Mascarenhas L, Venkatramani R. Hepatoblastoma and hypoplastic kidneys: a new association. Pediatr Blood Cancer. 2014;61:1476-8 pubmed publisher

Sonobe S, Inoue K, Tachibana S, Shiojiri M, Maeda T, Nakanishi N, et al. A case of pulmonary mucoepidermoid carcinoma responding to carboplatin and paclitaxel. Jpn J Clin Oncol. 2014;44:493-6 pubmed publisher

Chen P, Zhang Y, Polireddy K, Chen Q. The tumor-suppressing activity of the prenyl diphosphate synthase subunit 2 gene in lung cancer cells. Anticancer Drugs. 2014;25:790-8 pubmed publisher

Bhattacharya B, Low S, Soh C, Kamal Mustapa N, Beloueche Babari M, Koh K, et al. Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. Br J Pharmacol. 2014;171:3255-67 pubmed publisher

Kimura H, Uegaki M, Aoyama T, Kawai J, Hamano T, Hashimura T. [Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report]. Hinyokika Kiyo. 2014;60:39-43 pubmed

Gregory W, Corrias M, Tchirkov A, Swerts K, Vicha A, Dallorso S, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32:1074-83 pubmed publisher

Lauritsen J, Gundgaard M, Mortensen M, Oturai P, Feldt Rasmussen B, Daugaard G. Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy. Int J Cancer. 2014;135:1733-9 pubmed publisher

Sullivan E, Wilson M, Billups C, Wu J, Merchant T, Brennan R, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36:e335-40 pubmed publisher

Jakobsen J, Santoni Rugiu E, Sørensen J. Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140:645-52 pubmed publisher

Bradford L, Rauh Hain A, Clark R, Groeneweg J, Zhang L, BORGER D, et al. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol. 2014;133:346-52 pubmed publisher

Krivak T, Lele S, Richard S, Secord A, Leath C, Brower S, et al. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Am J Obstet Gynecol. 2014;211:68.e1-8 pubmed publisher

Aghajanian C, Goff B, Nycum L, Wang Y, Husain A, Blank S. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol. 2014;133:105-10 pubmed publisher

Kalita D, Shome D, Jain V, Chadha K, Bellare J. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J Ophthalmol. 2014;157:1109-15 pubmed publisher

Levine E, Stewart J, Shen P, Russell G, Loggie B, Votanopoulos K. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573-85 pubmed publisher

Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133:117-23 pubmed publisher

Hulshoff J, Smit J, van der Jagt E, Plukker J. Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients. Am J Surg. 2014;208:73-9 pubmed publisher

Bowden N. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?. Cancer Lett. 2014;346:163-71 pubmed publisher

Sinha G. Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all. J Natl Cancer Inst. 2014;106:djt447 pubmed publisher

Yokosuka T, Enomoto T, Takeda A, Kobayashi T. [Locally advanced granulocyte colony-stimulating factor-producing non-small cell lung cancer successfully treated with concurrent chemoradiotherapy]. Gan To Kagaku Ryoho. 2013;40:2330-2 pubmed

Choi C, Kim M, Park J, Yoon A, Kim H, Lee Y, et al. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer. 2014;22:1181-7 pubmed publisher

Nishio S, Ushijima K, Shimizu T, Tachibana T, Nasu H, Aiko K, et al. [Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer]. Gan To Kagaku Ryoho. 2013;40:2539-43 pubmed

Steingart R, Yadav N, Manrique C, Carver J, Liu J. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol. 2013;40:690-708 pubmed publisher

Watanabe K, Shinkai M, Goto H, Yoshikawa S, Yamaguchi N, Hara Y, et al. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. Tumori. 2013;99:e172-6 pubmed publisher

Minami S, Kijima T, Komuta K, Kumagai T, Imamura F, Yokota S, et al. Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous non-small cell lung cancer. Anticancer Res. 2013;33:5535-42 pubmed

Becker J, Weiss J, Theile D. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation. Toxicol Lett. 2014;225:43-7 pubmed publisher

Chantada G, Fandino A, Schvartzman E, Raslawski E, Schaiquevich P, Manzitti J. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr Blood Cancer. 2014;61:821-6 pubmed publisher

Koma Y, Nakashima N, Koyama M, Goto K, Yokota N, Kimura K, et al. [Two cases of recurrent invasive mucinous adenocarcinoma of the lung showing marked responses to platinum-based chemotherapyregimens with pemetrexed and bevacizumab]. Gan To Kagaku Ryoho. 2013;40:1525-8 pubmed

Yano T, Kawashiri T, Egashira N, Oishi R. [Substance P in antitumor drug-induced adverse reactions]. Nihon Yakurigaku Zasshi. 2013;142:255 pubmed

Muto M, Nishio S, Takemoto S, Ota S, Sonoda G, Ushijima K, et al. [A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin]. Gan To Kagaku Ryoho. 2013;40:1419-21 pubmed

Maenaka T, Iwata N, Egawa Takata T, Fukuda Y, Tsukahara C, Kashihara H, et al. [A case of poorly differentiated adenocarcinoma of the uterine cervix treated with paclitaxel and carboplatin after positive PAX 8 immunostaining]. Gan To Kagaku Ryoho. 2013;40:1413-7 pubmed

Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, et al. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. Cancer Chemother Pharmacol. 2013;72:1353-9 pubmed publisher

Fukuoka K, Yanagisawa T, Suzuki T, Wakiya K, Matsutani M, Sasaki A, et al. Successful treatment of hemorrhagic congenital intracranial immature teratoma with neoadjuvant chemotherapy and surgery. J Neurosurg Pediatr. 2014;13:38-41 pubmed publisher

Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, et al. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Int J Cancer. 2014;134:1796-809 pubmed publisher

Patel J, Socinski M, Garon E, Reynolds C, Spigel D, Olsen M, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage I. J Clin Oncol. 2013;31:4349-57 pubmed publisher

Nagar H, Boothe D, Parikh A, Yondorf M, Parashar B, Gupta D, et al. Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer. Int J Radiat Oncol Biol Phys. 2013;87:665-9 pubmed publisher

Liew M, Azad A, Tafreshi A, Eapen R, Bolton D, Davis I, et al. USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer. BJU Int. 2013;112 Suppl 2:74-82 pubmed publisher

Lee Y, Park W, Huh S, Yoon A, Park J, Choi C, et al. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis. Anticancer Res. 2013;33:4675-81 pubmed

Kawahara M, Atagi S, Komuta K, Yoshioka H, Kawasaki M, Fujita Y, et al. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer. Anticancer Res. 2013;33:4631-7 pubmed

Tarhini A, Zahoor H, McLaughlin B, Gooding W, Schmitz J, Siegfried J, et al. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res. 2013;33:4475-81 pubmed

Caffrey P, Frenkel G. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite. Anticancer Res. 2013;33:4249-54 pubmed

Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131:679-82 pubmed publisher

Shapiro J, ten Kate F, van Hagen P, Biermann K, Wijnhoven B, van Lanschot J. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258:678-88; discussion 688-9 pubmed publisher

Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S, et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol. 2013;131:531-4 pubmed publisher

Feuer G, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol. 2013;131:520-4 pubmed publisher

Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, et al. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131:567-73 pubmed publisher

Fruscio R, Sina F, Dolci C, Signorelli M, Crivellaro C, Dell Anna T, et al. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131:689-93 pubmed publisher

Otsuka I, Takaya H, Takagi K, Tanaka A, Kaseki H, Izuta C, et al. [Carcinosarcoma of the ovary treated with paclitaxel and carboplatin chemotherapy - a report of 4 cases]. Gan To Kagaku Ryoho. 2013;40:1249-53 pubmed

de Castria T, da Silva E, Góis A, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013;:CD009256 pubmed publisher

Ding Q, Zhan J. Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther. 2013;7:681-9 pubmed publisher

Karam I, Jiang S, Khaira M, Lee C, Schellenberg D. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol. 2015;38:51-4 pubmed publisher

Eroglu C, Kaynar L, Orhan O, Keklik M, Sahin C, Yildiz O, et al. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Am J Clin Oncol. 2015;38:68-73 pubmed publisher

Campos Parra A, Zuloaga C, Manríquez M, Aviles A, Borbolla Escoboza J, Cardona A, et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol. 2015;38:33-40 pubmed publisher

Gebhardt B, Mendenhall C, Morris C, Kirwan J, McAfee W, Mendenhall W. Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue. Am J Clin Oncol. 2014;37:535-8 pubmed publisher

Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol. 2015;38:28-32 pubmed publisher

Ashur Fabian O, Blumenthal D, Bakon M, Nass D, Davis P, Hercbergs A. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature. Anticancer Drugs. 2013;24:315-23 pubmed publisher

Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen J, Quereux G, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014;25:424-7 pubmed publisher

Shaikh F, Nathan P, Hale J, Uleryk E, Frazier L. Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials. Pediatr Blood Cancer. 2013;60:587-92 pubmed publisher

Kushner B, Modak S, Kramer K, Basu E, Roberts S, Cheung N. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013;119:665-71 pubmed publisher

Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692-8 pubmed publisher

Zekri J. Case report and review of literature: temporary asymptomatic sinus bradycardia with carboplatin, paclitaxel and bevacizumab: under-reported in clinical trials and under-disclosed in practice. Gulf J Oncolog. 2011;:60-4 pubmed

Collins I, Roberts Thomson R, Faulkner D, Rischin D, Friedlander M, Mileshkin L. Carboplatin dosing in ovarian cancer: problems and pitfalls. Int J Gynecol Cancer. 2011;21:1213-8 pubmed publisher

Ito H, Aoki Y, Oyama N, Miwa Y, Akino H, Yokoyama O. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy]. Gan To Kagaku Ryoho. 2011;38:481-4 pubmed

Moncharmont C, Auberdiac P, Mélis A, Afqir S, Pacaut C, Chargari C, et al. [Cisplatin or carboplatin, that is the question]. Bull Cancer. 2011;98:164-75 pubmed publisher

Li C, Sun Y, Pan Y, Wang Q, Yang S, Chen H. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis. Lung. 2010;188:359-64 pubmed publisher

Hulin A, Chatelut E, Royer B, Le Guellec C. [Level of evidence for therapeutic drug monitoring of carboplatin]. Therapie. 2010;65:157-62 pubmed publisher

Cowper Smith C, Dingle R, Guo Y, Burkard R, Phillips D. Synchronous auditory nerve activity in the carboplatin-chinchilla model of auditory neuropathy. J Acoust Soc Am. 2010;128:EL56-62 pubmed publisher

Wu Y, Chang J, Chao T. Paclitaxel and carboplatin-induced complete remission in peritoneal carcinomatosis of unknown origin: a report of two cases and review of the literature. Tumori. 2010;96:336-9 pubmed

Isoyama Y, Shioyama Y, Nomoto S, Ohga S, Nonoshita T, Onishi K, et al. Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: three cases and review of the literature. Jpn J Radiol. 2010;28:181-7 pubmed publisher

Hudson E, Lester J. Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. Eur J Cancer Care (Engl). 2010;19:324-8 pubmed publisher

Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med. 2009;13:1358-70 pubmed publisher

Natarajan G, Malathi R, Holler E. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999;58:1625-9 pubmed

Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol. 1999;125:156-65 pubmed

Heudi O, Mercier Jobard S, Cailleux A, Allain P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin. Biopharm Drug Dispos. 1999;20:107-16 pubmed

Oguri T, Katoh O, Takahashi T, Isobe T, Kuramoto K, Hirata S, et al. The Krüppel-type zinc finger family gene, HKR1, is induced in lung cancer by exposure to platinum drugs. Gene. 1998;222:61-7 pubmed